The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 52,600 |
| Share-based compensation expense | 16,200 |
| Depreciation and amortization | 95,800 |
| Change in fair value of contingent obligations, net | 0 |
| Amortization of deferred financing costs | 9,800 |
| Deferred income taxes | -4,000 |
| Noncash gain on sale of business | 0 |
| Change in fair value of warrant liability | 5,500 |
| Goodwill impairment | 0 |
| Impairment of long-lived assets | 12,200 |
| Loss on disposal of assets | -4,500 |
| Other | -400 |
| Accounts receivable | -25,500 |
| Inventories | 30,300 |
| Prepaid expenses and other assets | -11,700 |
| Accounts payable | -8,400 |
| Accrued expenses and other liabilities | -10,200 |
| Long-term incentive plan accrual | 3,100 |
| Accrued compensation | -17,300 |
| Income taxes receivable and payable, net | -1,700 |
| Contract liabilities | 5,200 |
| Net cash provided by (used in) operating activities | 170,600 |
| Purchases of property, plant and equipment | 13,800 |
| Proceeds from sale of property, plant and equipment | 38,200 |
| Milestone payments from prior asset divestiture | -50,000 |
| Purchase of convertible note receivable | 5,000 |
| Proceeds from sale of business | 0 |
| Net cash provided by investing activities | 69,400 |
| Proceeds from the issuance of debt, net of lender fees | 0 |
| Proceeds allocated to warrants issued in conjunction with debt | 0 |
| Proceeds allocated to common stock issued in conjunction with debt | 0 |
| Principal payments on term loan facility | 100,000 |
| Proceeds from revolving credit facility | 0 |
| Principal payments on revolving credit facility | 0 |
| Debt issuance costs | 0 |
| Proceeds from issuance of common stock upon exercise of stock options | 2,200 |
| Repurchase of debt | 8,700 |
| Prepayment premium on debt principal payment | 3,800 |
| Purchases of treasury stock | 24,900 |
| Proceeds from share-based compensation activity | 0 |
| Proceeds from at-the-market sale of stock, net of commissions and expenses | 0 |
| Taxes paid for share-based compensation activity | 1,400 |
| Net cash used in financing activities | -136,600 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 100 |
| Net change in cash, cash equivalents and restricted cash | 103,500 |
| Cash, cash equivalents and restricted cash, beginning of period | 105,600 |
| Cash, cash equivalents and restricted cash, end of period | 209,100 |
Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS)